Stem cell injection for lung scarring
Part of Lungs & breathing clinical trials.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a confirmed diagnosis of IPF (a specific type of lung scarring).
- Your lung function tests must be within certain ranges: FVC% between 50 and 90, DLCO% between 30 and 90 (these are breathing tests your doctor does).
- You must be on a stable dose of either nintedanib or pirfenidone for at least 8 weeks before starting.
- You need to have a resting oxygen level of at least 60 mmHg and be able to walk at least 150 meters in 6 minutes.
- You must agree to use effective birth control during the study if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled therapy made from tiny particles derived from placental cells, which may help reduce scarring in the lungs. It is a phase 1 study, so the main goal is to check safety and see if the treatment has any effect on IPF.
This trial tests a new cell-based therapy for people with IPF, a lung condition that causes scarring and breathing problems. The goal is to see if the treatment can help slow the disease and improve breathing ability.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial tests a new immune-based therapy called CAR-DC for people with advanced IPF whose disease is still getting worse despite standard treatments. It aims to slow down or stop the scarring in the lungs, offering a new option for those who are not getting a lung transplant.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.